Published in Br J Pharmacol on May 08, 2007
Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One (2017) 0.75
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 27.60
Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A (1990) 16.34
Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A (1987) 14.22
Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1991) 7.26
Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1991) 7.11
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2006) 6.07
Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest (1989) 5.01
Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A (1998) 4.94
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol (1986) 3.66
Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest (1991) 3.18
Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15
Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature (1992) 3.14
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol (2001) 2.82
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest (1990) 2.61
Elective cardiac arrest. Lancet (1955) 2.22
Mechanism of myocardial "stunning". Circulation (1990) 2.16
Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. J Mol Cell Cardiol (1984) 2.03
Selective hypothermia of the heart in anoxic cardiac arrest. Surg Gynecol Obstet (1959) 1.87
Regulation of basal myocardial function by NO. Cardiovasc Res (1999) 1.83
Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol (1991) 1.81
L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation (1997) 1.75
Ischaemia-reperfusion injury. Br J Surg (1994) 1.72
Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest (2002) 1.70
Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol (2005) 1.68
Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res (1993) 1.63
Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol (1993) 1.62
The heparin-binding domain of extracellular superoxide dismutase C and formation of variants with reduced heparin affinity. J Biol Chem (1992) 1.55
Organ preservation. Annu Rev Med (1995) 1.43
Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res (2002) 1.42
Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2002) 1.39
Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res (1998) 1.39
NOS substrate during cardioplegic arrest and cold storage decreases stunning after heart transplantation in a rat model. J Heart Lung Transplant (2003) 1.39
Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization. Ann Thorac Surg (1998) 1.38
Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med (1991) 1.33
Is blood superior to crystalloid cardioplegia? A meta-analysis of randomized clinical trials. Circulation (2006) 1.32
The role of oxygen-derived free radicals in ischemia-induced increases in canine skeletal muscle vascular permeability. Circ Res (1985) 1.24
Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg (Torino) (1975) 1.22
Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet (1994) 1.20
Direct measurement of nitric oxide generation from nitric oxide synthase. Proc Natl Acad Sci U S A (1997) 1.20
Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J Clin Invest (1991) 1.20
A proposed "solution" to the cardioplegic controversy. J Thorac Cardiovasc Surg (1979) 1.19
Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol (1992) 1.17
Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol (1997) 1.16
ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol (1992) 1.14
The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol (1996) 1.13
Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest (1994) 1.10
Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol (1997) 1.09
Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res (1999) 1.09
Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension (2002) 1.09
Studies of the effects of hypothermia on regional myocardial blood flow and metabolism during cardiopulmonary bypass. I. The adequately perfused beating, fibrillating, and arrested heart. J Thorac Cardiovasc Surg (1977) 1.08
Regulation of endothelial nitric oxide synthase activity and gene expression. Ann N Y Acad Sci (2002) 1.08
Delivery of exogenous tetrahydrobiopterin (BH4) to cells of target organs: role of salvage pathway and uptake of its precursor in effective elevation of tissue BH4. Mol Genet Metab (2005) 1.08
Heart preservation for transplantation: principles and strategies. Ann Thorac Surg (1999) 1.07
Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation (1997) 1.07
Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol (2002) 1.06
Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res (1999) 1.01
Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am J Physiol (1992) 1.01
S-nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation (2002) 1.01
NO and cardiac diastolic function. Cardiovasc Res (1999) 1.00
Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol (1995) 0.99
Cold cardioplegia or continuous coronary perfusion? Report on preliminary clinical experience as assessed cytochemically. J Thorac Cardiovasc Surg (1977) 0.98
Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation (1997) 0.98
Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation (2003) 0.95
The horror autotoxicus and multiple-organ failure. Arch Surg (1992) 0.95
Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. J Thorac Cardiovasc Surg (2002) 0.95
Bradykinin induces microvascular preconditioning through the opening of calcium-activated potassium channels. Surgery (2006) 0.94
Nitric oxide protects cardiac sarcolemmal membrane enzyme function and ion active transport against ischemia-induced inactivation. J Biol Chem (2003) 0.93
Bradykinin protects the rabbit heart after cardioplegic ischemia via NO-dependent pathways. Ann Thorac Surg (2000) 0.92
Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol (1997) 0.90
Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc Surg (1994) 0.89
L-arginine during long-term ischemia: effects on cardiac function, energetic metabolism and endothelial damage. J Heart Lung Transplant (2000) 0.89
Donors of nitric oxide mimic effects of ischaemic preconditioning on reperfusion induced arrhythmias in isolated rat heart. Mol Cell Biochem (1997) 0.87
Coronary endothelial dysfunction after ischemia and reperfusion: a new therapeutic target? Braz J Med Biol Res (2001) 0.86
Bradykinin preconditioning improves the profile of cell survival proteins and limits apoptosis after cardioplegic arrest. Circulation (2005) 0.86
Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2003) 0.85
Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol (2003) 0.84
Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2001) 0.84
The effect of two different diltiazem treatments on infarct size in ischemic, reperfused porcine hearts. Circulation (1984) 0.84
Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation (1996) 0.83
Time-dependent increase in nitric oxide formation concurrent with vasodilation induced by sodium nitroprusside, 3-morpholinosydnonimine, and S-nitroso-N-acetylpenicillamine but not by glyceryl trinitrate. Drug Metab Dispos (1995) 0.83
Kinins and cardioprotection. Pharmacol Res (1997) 0.82
Reduction of lipid peroxidation in reperfused isolated rabbit hearts by diltiazem. Circ Res (1989) 0.82
Role of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J Cardiovasc Surg (Torino) (2003) 0.81
Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation (1995) 0.81
A macrocyclic nitrosyl ruthenium complex is a NO donor that induces rat aorta relaxation. Nitric Oxide (2004) 0.81
S-nitroso human serum albumin attenuates ischemia/reperfusion injury after cardioplegic arrest in isolated rabbit hearts. J Heart Lung Transplant (2005) 0.80
The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest. Br J Pharmacol (1996) 0.80
ACE-inhibition attenuates cardiac cell damage and preserves release of NO in the postischemic heart. Immunopharmacology (1999) 0.80
A novel heparin-binding, human chimeric, superoxide dismutase improves myocardial preservation and protects from ischemia-reperfusion injury. J Heart Lung Transplant (2002) 0.80
Cardioprotective effects of recombinant human extracellular-superoxide dismutase type C in rat isolated heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol (1991) 0.80
Nitric oxide-mediated, endothelium-dependent vasodilation is selectively attenuated in the postischemic extremity. Surgery (1993) 0.79
The effect of L-arginine on myocardial recovery after cardioplegic arrest and ischemia under moderate and deep hypothermia. Circulation (1997) 0.79
Critical timing of nitric oxide supplementation in cardioplegic arrest and reperfusion. Circulation (1996) 0.79
Efficiency of L-arginine enriched cardioplegia and non-cardioplegic reperfusion in ischemic hearts. Int J Cardiol (2004) 0.78
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg (1995) 0.78
Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model. J Cardiovasc Pharmacol (1996) 0.78
The cell in shock: the origin of multiple organ failure. Resuscitation (1991) 1.08
Simultaneous determination of myocardial nucleotides, nucleosides, purine bases and creatine phosphate by ion-pair high-performance liquid chromatography. J Chromatogr (1992) 1.04
Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol (2008) 0.93
The erythrocyte-perfused "working heart" model: hemodynamic and metabolic performance in comparison to crystalloid perfused hearts. J Pharmacol Toxicol Methods (1999) 0.84
Hyperdynamic sepsis in baboons: I. Aspects of hemodynamics. Circ Shock (1991) 0.83
S-nitroso human serum albumin given after LPS challenge reduces acute lung injury and prolongs survival in a rat model of endotoxemia. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Preliminary data on isolation of an elastase-like proteinase and its inhibitor from ovine neutrophil granulocytes. Biol Chem Hoppe Seyler (1988) 0.79
Desensitization of rat cardiomyocyte adenylyl cyclase stimulation by plasma of noradrenaline-treated patients with septic shock. Circ Shock (1993) 0.77
Inhibition of human, ovine, and baboon neutrophil elastase with Eglin c and secretory leukocyte proteinase inhibitor. Biol Chem Hoppe Seyler (1992) 0.77
Mechanisms in acute septic cardiomyopathy: evidence from isolated myocytes. Basic Res Cardiol (1992) 0.76
Lipidperoxidation in a canine model of hypovolemic-traumatic shock. Prog Clin Biol Res (1989) 0.76
New HTK-N46B cardioplegia provides superior protection during ischemia/reperfusion in failing hearts. J Cardiovasc Surg (Torino) (2013) 0.76
Diltiazem during reperfusion preserves high energy phosphates by protection of mitochondrial integrity. Eur J Cardiothorac Surg (2002) 0.76
High-performance liquid chromatographic determination of p-aminohippuric acid and iothalamate in human serum and urine: comparison of two sample preparation methods. J Chromatogr B Biomed Sci Appl (2000) 0.76
Oxidatively modified plasma phospholipids containing reactive carbonyl functions measured by HPLC: evidence for phosphatidylcholine-bound aldehydes in plasma of burn patients. Free Radic Res (1995) 0.75
Characterization of sheep alpha-1-proteinase inhibitor: important differences from the human protein. Am Rev Respir Dis (1988) 0.75
Studies on low molecular weight inotropic plasma substances in prolonged hypovolemic traumatic shock. Prog Clin Biol Res (1987) 0.75
Proteolysis and lipid peroxidation--two aspects of cell injury in experimental hypovolemic-traumatic shock. Adv Exp Med Biol (1988) 0.75
The enzymatic and release characteristics of sheep neutrophil elastase: a comparison with human neutrophil elastase. Biol Chem Hoppe Seyler (1992) 0.75
[Acute septic cardiomyopathy: a manifestation in multi-organ failure in infection?]. Med Klin (Munich) (1991) 0.75